Psyence Labs Ltd. Acquires 30.05% Stake in PSYENCE BIOMEDICAL LTD. via $5M Share Exchange
PBM has more than doubled off its 52-week low of $1.92.
Summary
Psyence Labs Ltd. has become a major shareholder in PSYENCE BIOMEDICAL LTD., acquiring over 30% of the company through a $5 million share exchange as a result of a pre-existing agreement.
Key Events · Ownership and Investor Activity · PBM
-
Significant Stake Acquired
Psyence Labs Ltd. acquired 1,146,159 common shares, representing 30.05% of PSYENCE BIOMEDICAL LTD.'s outstanding shares.
-
$5 Million Share Exchange
The acquisition was a share-for-share exchange valued at $5,000,000, where Psyence Labs Ltd. issued its own ordinary shares to PSYENCE BIOMEDICAL LTD. in consideration.
-
Exercise of Put Option
This transaction resulted from the exercise of an irrevocable put option granted under a Share Put Option and Amendment Agreement dated July 3, 2025, and previously disclosed on February 13, 2026.
Analysis · PBM · Life Sciences
Psyence Labs Ltd. has acquired a 30.05% ownership stake in PSYENCE BIOMEDICAL LTD. through a share-for-share exchange valued at $5 million. This transaction, which occurred on February 25, 2026, resulted from the exercise of a previously disclosed put option. The acquisition of such a significant stake by a strategic entity is a major capital event for the company, especially given its small market capitalization, and represents a substantial change in its ownership structure.
At the time of this filing, PBM was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $1.92 to $74.94. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.